Intravitreal avacincaptad pegol demonstrates promising results for geographic atrophy

Intravitreal avacincaptad pegol (ACP) has shown promising results in two Phase 3 pivotal trials for the treatment of geographic atrophy (GA), a progressive and vision-threatening eye disease, according to data presented at ASRS 2023. ACP, a pegylated RNA aptamer that inhibits complement C5, demonstrated a significant reduction in the progression...